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Background: IL-6 signaling plays a role in immune and skeletal systems.
Results: sIL-6Rmediated PTH-dependent hematopoietic cell expansions and blocking sIL-6R reduced PTH anabolic actions in
mice.
Conclusion: sIL-6R is a mediator of PTH hematopoietic actions in marrow and anabolic actions in bone.
Significance: Novel orphan sIL-6R functions support PTH actions in bone and bone marrow.
Both PTH and IL-6 signaling play pivotal roles in hematopoi-
esis and skeletal biology, but their interdependence is unclear.
The purpose of this study was to evaluate the effect of IL-6 and
soluble IL-6 receptor (sIL-6R) on hematopoietic and skeletal
actions of PTH. In the bonemicroenvironment, PTHstimulated
sIL-6R protein levels in primary osteoblast cultures in vitro and
bone marrow in vivo in both IL-6/ and IL-6/ mice. PTH-
mediated hematopoietic cell expansion was attenuated in
IL-6/ compared with IL-6/ bone marrow, whereas sIL-6R
treatment amplified PTH actions in IL-6/ earlier than
IL-6/ marrow cultures. Blocking sIL-6R signaling with
sgp130 (soluble glycoprotein 130 receptor) inhibited PTH-de-
pendent hematopoietic cell expansion in IL-6/ marrow. In
the skeletal system, although intermittent PTH administration
to IL-6/ and IL-6/mice resulted in similar anabolic actions,
blocking sIL-6R significantly attenuated PTH anabolic actions.
sIL-6R showed no direct effects on osteoblast proliferation or
differentiation in vitro; however, it up-regulated myeloid cell
expansion and production of the mesenchymal stem cell
recruiting agent, TGF-1 in the bone marrow microenviron-
ment. Collectively, sIL-6R demonstrated orphan function and
mediated PTH anabolic actions in bone in association with sup-
port of myeloid lineage cells in the hematopoietic system.
Parathyroid hormone (PTH)2 is a well known modulator of
calcium homeostasis with anabolic and catabolic actions in
bone (1, 2). Based on its prominent anabolic actions, intermit-
tent administration of PTH 1–34 is an effective therapeutic
option for established osteoporosis and is emerging as a poten-
tial therapy for inflammatory mediated bone disease (3, 4). A
growing body of evidence suggests an interaction between the
skeletal and hematopoietic systems in the bone marrow
microenvironment (9, 10). PTH positively supports the hema-
topoietic system by stimulating osteoblastic secretion of hema-
topoietic factors, such as IL-6 and MCP-1(CCL2) (5–8).
Because PTH has notable actions in these systems, several
investigators have suggested that PTH plays an essential role in
the cross-talk between the skeletal and hematopoietic systems
(5, 7, 11).
IL-6 is a well established downstream mediator of PTH sig-
naling (12–14). PTH stimulates mRNA expression, protein
synthesis, and secretion of IL-6 in vitro and in vivo (12–14).
Similar to PTH, IL-6 signaling also plays dual actions in both
the hematopoietic and skeletal system. IL-6 stimulates prolifer-
ation of early hematopoietic progenitor cells (15) and mediates
PTH-dependent hematopoietic cell expansion (6). In the skel-
etal system, it has been reported that IL-6 stimulates osteoclast
differentiation in vitro (16) and mediates PTH induced bone
resorption in vivo (17). Relative to bone formation, IL-6 has
been found to support osteoblast generation through the
gp130-STAT1/3 pathway (18). As of yet, details linking PTH,
IL-6, and their actions on bone and hematopoietic cells are ill
defined.
In classic signaling, IL-6 acts through a receptor complex,
composed of the membrane-bound IL-6 receptor (IL-6R) and
gp130 (19). Alternatively, IL-6 also binds to its soluble receptor,
sIL-6R. The IL-6sIL-6R complex signals through the gp130
homodimer withoutmembrane-associated IL-6R and is known
as “IL-6 transsignaling” (20). Both IL-6 classic signaling and
transsignaling similarly lead to the activation of STAT1,
STAT3, and the MAPK pathway (21, 22). Recently, sIL-6R has
been reported to play a central role in several inflammatory and
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autoimmune diseases, by regulating systemic or local actions of
IL-6 signaling (23, 24). However, the role of sIL-6R in the bone
marrow microenvironment and in the context of PTH actions
remains elusive. The purpose of this studywas to investigate the
impact of sIL-6R in PTH-mediated hematopoietic cell expan-
sion and to delineate the relationship between hematopoietic
and skeletal actions of PTH through sIL-6R signaling.
EXPERIMENTAL PROCEDURES
Reagents—Antibodies for flow cytometric analyses included
anti-mouseGr-1, B220, CD19, CD3, F4/80, and STAT3(pY705)
which, along with the FITC annexin V staining kit for flow
cytometry, were obtained from BD Biosciences (San Jose, CA).
Anti-mouse CD11b antibody was purchased by eBioscience
(San Diego, CA). Serum TRAP5b and P1NP immunoassays
were obtained from Immunodiagnostic Systems Ltd. (Fountain
Hills, AZ). The mouse sIL-6R DuoSet ELISA development sys-
tem, TGF-1 Quantikine ELISA system, recombinant mouse
sIL-6R, mouse IL-6, and human sgp130 were purchased from
R & D Systems (Minneapolis, MN).
Animal Care and Experiments—All of the animal experi-
mentswere performed in compliancewith the institutional eth-
ical requirements and approved by the University of Michigan
Committee for the Use and Care of Animals. C57B6 IL-6/
mice (25) were kindly provided by Evan Keller (University of
Michigan, Ann Arbor, MI), and breeding was established to
generate desired genotypes.
To evaluate anabolic actions of PTH, IL-6/ and IL-6/
mice at 3–24 days (young) or 16–22 weeks (adult) of age were
used. The mice received daily subcutaneous injections of vehi-
cle (saline) or 50 g/kg human PTH (hPTH 1–34; Bachem,
Torrance, CA) for 3 (young) or 6 (adult) weeks. For fluoro-
chrome labeling, calcein (20 mg/kg) (Sigma-Aldrich) dis-
solved in buffer (0.15 M NaCl, 2% NaHCO3) was injected
intraperitoneally to adult mice at 5 and 2 days prior to sac-
rifice. For treatment with sgp130, the mice received daily
subcutaneous injections of vehicle (PBS) or sgp130 (0.3
g/mice) 1 h prior to vehicle (saline) or hPTH (50 g/kg)
injection. This regimen was followed for 2 weeks. All of the
mice were sacrificed at least 24 h after the last injection in all
of the above experiments.
Measurement of sIL-6R in Cell Cultures, Blood, and Bone
Marrow Serums—For measurement of osteoblast production
of sIL-6R, primary calvarial cells from IL-6/ or IL-6/mice
were plated (3 106/well) in 12-well plates overnight following
PTH (10 nM) treatment in -MEM including 1% FBS. Culture
media were harvested and used for sIL-6R measurement at 12
and 24 h after PTH treatment, and untreatedmediumat 0 hwas
used for control. For in vivo measurement of sIL-6R, young (3
weeks) and adult (16weeks) IL-6/ and IL-6/mice received
intermittent PTH or vehicle (saline) injection for 2 weeks and
were sacrificed 5–6 h after the last injection. At sacrifice, whole
blood was obtained by intracardiac blood draw, and serum was
separated and kept frozen until biochemical assays were per-
formed. Total bone marrow was centrifuged from hindlimb
bones into PBS containing a proteinase inhibitor mixture (Sig-
ma-Aldrich), and supernatant was transferred and frozen until
assay. For measuring bone marrow sIL-6R levels, the cells were
seeded at 6 106/well in 24-well plates and cultured for 8 days,
and whole cells and conditioned media were harvested at
days 1 and 8. In parallel experiments, the cells were seeded at
4 106/well in 24-well plates and treated once with or with-
out fms-like tyrosine kinase-3 ligand (Flt-3L) (0.1 g/ml)
and/or PTH (10 nM), and whole cells and conditioned media
were harvested at days 1, 6, and 8. Supernatants were used
for measurement of sIL-6R. The remaining cells were lysed
in buffer (CelLyticMT; Sigma-Aldrich), and the protein con-
centrations were measured by Lowry method using the DC
protein assay kit (Bio-Rad). Levels of sIL-6R were adjusted by
total protein concentrations of cell lysates. The sIL-6R levels
were measured using ELISA according to the manufacturer’s
protocols.
Ex Vivo Cell Amplification Study and Flow Cytometric
Analyses—The ex vivo amplification protocol is based on
Servet-Delprat’s model system and utilized to examine PTH
actions as we have described previously (26). In brief, total bone
marrow cells from IL-6/ or IL-6/ mice (4–6 weeks old)
were seeded at 2.5 105/cm2 in IMDM (RPMI or -MEMwas
also used in the supplementary data set) supplemented with
20% fetal bovine serum, 100 units/ml penicillin, 50g/ml strep-
tomycin, and 1% glutamine. At the time of plating, the cells
were treated once with Flt-3L (0.1 g/ml) and/or PTH (10 nM).
For sIL-6R treatment, all groups received vehicle or sIL-6R (0.5
g/ml) alone or in conjunctionwith designated treatments. For
sgp130 treatment, the cells were pretreated with vehicle or
sgp130 (1 g/ml) for 1 h and then treated once with Flt-3L (0.1
g/ml) and/or PTH (10 nM). The cells were enumerated using a
hemocytometer on day 6 or 8, and cell viability was determined
by trypan blue dye exclusion. Flow cytometric analyses (FACS)
were performed for cell characterization at day 6 or 8. Nonad-
herent cells (1  106/sample) were pelleted, rinsed with PBS,
resuspended in cold FACS buffer, and incubated for 30 min at
4 °C with appropriate antibodies while protected from light
exposure. To analyze cell apoptosis, the FITC annexin V apo-
ptosis assay system was used according to the manufacturer’s
protocol.
Phospho-flow Cytometric Analyses for BoneMarrow pSTAT3—
For ex vivo studies, whole bone marrows from 4-week-old
IL-6/ and IL-6/ mice were treated once with vehicle
(VEH), PTH (10 nM), or PTH with 1-h pretreatment of sgp130
and treated once with VEH, IL-6 (20 ng/ml), or sIL-6R (0.5
g/ml) immediately after isolation. For in vivo studies, 3-week-
old IL-6/ mice received single injections of vehicle (PBS) or
sgp130 (0.3g/mice) 1 h prior to PTH injection (50g/kg) and
were sacrificed 2 h after PTH injection. Total bonemarrow cells
were flushed with fixation buffer (0.37% formaldehyde). To
analyze STAT3 phosphorylation, the cells were treated with
Lyse/Fix buffer (BDBiosciences) for 15min at 37 °C followed by
permeabilization with Perm buffer IV (BD Biosciences) for 20
min at room temperature. After washing with FACS buffer, the
cells were stainedwithmouse anti-STAT3(pY705) antibody for
60 min at room temperature, and the frequency of pSTAT3
cells was analyzed using the FACSCalibur system and Cell
Quest Pro software (BD Biosciences). To determine the
pSTAT3 status inCD11bGR-1 cells, bonemarrow cells were
flushed with fixation solution, washed twice in cold FACS
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buffer (PBSwith 2%FBS and 2mMEDTA), and stainedwith cell
surfacemarkers, mouse CD11b, andGr-1 antibodies for 30min
at 37 °C followed by cell permeabilization and staining with
mouse anti-STAT3(pY705) antibody. The cells were analyzed
as described above.
Histologic Assays—Tibiae, femurs, or vertebrae were fixed in
10% phosphate-buffered formalin for 24 (young mice) or 48 h
(adult mice) at 4 °C and decalcified in 10% EDTA for 10 (young
mice) or 21 days (adult mice) at room temperature. Paraffin-
embedded tibiae, femurs, and vertebrae were cut (5 m) and
stained with hematoxylin and eosin, and bone areas were
measured using a computer-assisted histomorphometric
analyzing system (Osteomeasure; OsteoMetrics Inc. Atlanta,
GA). For tibiae and femurs, the region of interest began 200
m proximal to the growth plate and 50 m from the endo-
cortical surface, including a 1200-m (width)  800-m
(length) area.
For dynamic histomorphometric analysis, tibiae from
adult mice were fixed, dehydrated in xylene and graded etha-
nols without decalcification, and embedded in modified
methylmethacrylate. Sections were cut (8 m) with vertical
bed microtomes (2065 and 2165; Leica/Jung, Bannockburn,
IL) and affixed to gelatin-precoated (1%) slides. Calcein
labels were visualized in unstained slides under Nikon
Eclipse E800 light/epifluorescent microscopy to analyze
bone formation rate, mineral apposition rate, and mineral-
izing surface.
MicroCT—Right femorae were scanned in water using cone
beam microcomputed tomography (eXplore Locus SP; GE
Healthcare Pre-Clinical Imaging, London, Canada). All of the
images were reconstructed and calibrated at an 18-m voxel
size. A trabecular region of interest equal to 2 mm in length
beginning at 200 m proximal to the distal growth plate was
defined with a spline algorithm encompassing the endocortical
surface (MicroView v2.2 Advanced Bone Analysis Application;
GE Healthcare Pre-Clinical Imaging).
Quantitative RT-PCR-For RT-PCR, TaqMan universal PCR
Master Mix was used with the TGF-1 (Mm03024053_m1),
alkaline phosphatase (Mm00475831_m1), and osteocalcin
(Mm03413826_mH) probe/primer sets from Applied Biosys-
tems. Rodent GAPDH (VIC reporter dye) was used as an
endogenous control.
Cell Proliferation and Differentiation Assays—For cell prolif-
eration assays, calvarial cells were plated (50,000/well) in
24-well plates overnight followed by synchronization by serum
starvation for 12 h before sIL-6R (0.1 or 0.5 g/ml) or vehicle
treatment in 2% serum. The media with sIL-6R or vehicle were
changed every other day. The numbers of viable cells were
determined at the indicated times (days 1, 3, 4, and 5) by trypan
blue exclusion. For the osteogenic differentiation study, calvar-
ial cells (700,000/well) were plated in 12-well plates, and at con-
fluence, mineralization was initiated with osteogenic medium
(-MEM including 10% FBS, 50 g/ml L-ascorbic acid, and 10
mM -glycerophosphate) with or without PTH (10 nM) and/or
sIL-6R (0.5 g/ml). Osteogenic medium ( PTH  sIL-6R)
were refreshed every 2 days for 12 (for BMSC) or 14 days (cal-
varial cells), and Von Kossa staining was performed as
described previously (27).
Statistical Analyses—Statistical analysis was performed by
two-way analysis of variance or t test using theGraphPad Instat
statistical program with significance at p  0.05. For determi-
nation of PTH effects in each group, the values were expressed
as treatment over control prior to statistical analysis. The data
are presented as the means S.E.
RESULTS
Effect of PTH on sIL-6R Production in Bone—To evaluate the
effect of PTH on sIL-6R production in bone marrow, sIL-6R
protein levels were evaluated in young (3 weeks) and adult (16
weeks) IL-6/ and IL-6/ mice after intermittent PTH
administration for 2 weeks. Bone marrow sIL-6R levels were
significantly lower in young IL-6/ versus IL-6/ mice, and
PTH administration elevated sIL-6R in IL-6/ mice signifi-
cantly to wild type levels (Fig. 1A). In adult mice, both geno-
types showed similar bonemarrow sIL-6R levels, as well as sim-
ilar PTH increases (Fig. 1B). In contrast, serum sIL-6R levels
showed no difference between young IL-6/ and IL-6/
mice andwere not altered in response to PTH (data not shown).
To investigate the endogenous sIL-6R levels in an ex vivo
bonemarrow culture system, sIL-6R levelsweremeasured from
plated bone marrow over 8 days with or without a single PTH
and/or Flt-3L administration. At day 1, sIL-6R levels in
untreated IL-6/ cells were lower than those in IL-6/ cells
(0.01 versus 0.02 pg/ml/106 cells, p 0.01). PTH co-treatment
with Flt-3L, not PTH alone, significantly increased sIL-6R pro-
duction in both IL-6/ (Fig. 1C) and IL-6/ (Fig. 1D) cells,
whereas the extentwas relatively less in IL-6/ comparedwith
IL-6/ cells (24.2% versus 38.7% increase, p  0.05, note dif-
ferent y axis scale in IL-6/ versus IL-6/).
Because stromal cells and osteoblasts have PTH receptors in
the bone marrow microenvironment (28), sIL-6R levels were
measured in medium from primary calvarial cell cultures
treated with PTH. Although sIL-6R levels were lower in
IL-6/ than IL-6/ calvarial cell supernatants under basal
conditions, sIL-6R production was stimulated by PTH in cells
from both genotypes with a greater fold increase in IL-6/
cells at 24 h (Fig. 1, E and F). Collectively, PTH stimulated
sIL-6R production not only in IL-6/mice but also in IL-6/
mice, suggesting that sIL-6R alone, without IL-6 (i.e. sIL-6R
signaling), has orphan biological functions mediating PTH
signaling.
Effect of sIL-6R on exVivoHematopoietic Cell Expansion—To
verify sIL-6R orphan function, the ex vivo cell expansion study
was performed with sIL-6R treatment. As described previously
(6, 26), wholemarrows were isolated and expanded ex vivowith
Flt-3L, a stem cell factor that supports hematopoietic stem cell
expansion especially CD45 and CD11b cells. Exogenous
sIL-6Rwas introduced in this systemwith or without PTH (Fig.
2A). Consistent with previous findings (6), PTH amplified Flt-
3L-dependent cell expansion in IL-6/ cells at day 8. sIL-6R
significantly increased cell expansion regardless of PTH treat-
ment in IL-6/ cells at day 8 (Fig. 2B). In contrast, PTHhad no
effect on Flt-3L-dependent cell expansion in IL-6/ cells (Fig.
2C). However, sIL-6R combined with PTH significantly
increased cell expansion in IL-6/ cells at an earlier time point
(day 6) than in IL-6/ cells (Fig. 2, B versus C). Hence, cell
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characterizations were focused on day 6, which showed maxi-
mal effects of PTH on IL-6/ cells.
Our previous study reported that the PTH-mediated hema-
topoietic cell expansion was due to reduced cell apoptosis and
not to increased cell proliferation (6). Further analyses of
sIL-6R showed significantly decreased apoptosis in PTH-
treated cells at day 6 in IL-6/ cells (Fig. 2D), suggesting that
the effect of sIL-6R on cell expansion was at least in part due to
PTH anti-apoptotic actions.
To further characterize the PTH-dependent cell expansions
at day 6 in IL-6/ cells, several cell subsets were analyzed via
flow cytometry with exclusion of apoptotic (annexin V) cells.
sIL-6R significantly increased myeloid progenitor cells
(CD11bGr-1) (Fig. 2, E and F) and macrophages (F4/80)
(Fig. 2,G andH) under PTH-treated conditions at day 6. Other
lymphoid cells analyzed including CD3 (T cell), CD19 (B cell),
and B220 (B cell) showed no significant changes with sIL-6R
treatment (data not shown).
Effect of sgp130 on ex Vivo Hematopoietic Cell Expansion—
To further analyze the effect of sIL-6R signaling on hematopoi-
etic cell expansion, soluble gp130 receptor (sgp130), a specific
inhibitor of sIL-6R, was introduced in the ex vivo cell expansion
system (Fig. 3A). sgp130 significantly reduced the PTH-depen-
dent increases in total cell numbers in both IL-6/ (Fig. 3B)
and IL-6/ (Fig. 3C) marrow cells, suggesting that sgp130
inhibited not only IL-6sIL-6R transsignaling, actions from IL-6
and sIL-6R complex in IL-6/ cells, but also orphan sIL-6R
signaling, actions from sIL-6R alone in IL-6/ cells.Moreover,
sgp130 increased apoptosis in PTH-treated IL-6/ cells (Fig.
3D). Flow cytometric analyses of cell subtypes showed that
sgp130 significantly decreased myeloid progenitor cells (Fig. 3,
E and F), whereasmacrophages (Fig. 3G) or lymphoid cells (Fig.
3,H–J) were not affected in IL-6/ bonemarrow populations.
Collectively, sgp130 inhibited hematopoietic myeloid cell
expansion by supporting anti-apoptotic actions of PTH on
IL-6/ cells.
FIGURE 1. Effect of PTH on sIL-6R production in bone. A and B, young (A, 3 weeks) and adult (B, 16 weeks) male and female IL-6/ and IL-6/mice were
treatedwith PTH (50g/kg) or VEH for 2weeks. sIL-6R levels weremeasured in bonemarrow (n 9–11/group). C andD, whole bonemarrows from IL-6/ (C)
or IL-6/ (D) mice (4–6 weeks old, female) were seeded at 4 106 cells/well in 24-well plates and treated once with VEH or PTH and/or Flt-3L. sIL-6R protein
levels were measured from culture medium at days 1, 6, and 8. The graphs show the ratio of sIL-6R/total cell protein. Note the different y axis scales (n 
4/group). E and F, primary neonatal calvarial cells from IL-6/ (E) or IL-6/ (F) mice were plated overnight in 12-well dishes at 3 106/well followed by PTH
(10 nM) stimulation in 1% serum. Culture medium was harvested 0, 12, or 24 h after PTH stimulation. Endogenous sIL-6R levels were measured by ELISA (n
4/group). All of the numerical data are the means S.E. of two independent experiments. *, p 0.05; **, p 0.01; ***, p 0.001.
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Effect of sIL-6R Signaling on STAT3 Phosphorylation in
Hematopoietic Cells—To provide further mechanistic insight
of sIL-6R signaling on PTH actions in hematopoietic cells,
STAT3 phosphorylation, a major downstream transcriptional
factor of IL-6 signaling, was evaluated. pSTAT3 cells were
measured by flow cytometric analysis in IL-6/ and IL-6/
bone marrow 12 h after ex vivo PTH stimulation. The percent-
age of pSTAT3 cells was significantly increased with PTH
treatment in both IL-6/ and IL-6/ marrow cells, and
sgp130 inhibited PTH-mediated STAT3 phosphorylation only
in IL-6/ marrow cells (Fig. 4A and supplemental Fig. S1).
Furthermore, both IL-6 and sIL-6R significantly up-regulated
pSTAT3 in IL-6/ and IL-6/marrow cells from 0.5 to 12 h
(Fig. 4, B and C, and supplemental Fig. S2). Interestingly, in
IL-6/ marrow cells, sIL-6R signaling resulted in earlier
STAT3 phosphorylation than IL-6 (Fig. 4C and supplemental
Fig. S2). At 2 h, a greater percentage of IL-6/ marrow cells
demonstrated STAT3 phosphorylation in marrow populations
treated with sIL-6R as compared with those treated with IL-6.
After 6 h, the earlier effects of sIL-6R signaling on STAT3 phos-
phorylation were decreased, whereas the effects of IL-6 were
sustained at 12 h. Notably, the effect of sIL-6R on STAT3 phos-
phorylation in IL-6/marrows suggests that sIL-6R signaling
has orphan biological function downstream of PTH signaling.
Further, in vivo sgp130 treatment was performed with anal-
yses of STAT3 phosphorylation. Bone marrow cells were har-
vested from IL-6/ mice 2 h after a single treatment of PTH
alone or PTH combined with sgp130. Flow cytometric analyses
showed that PTH treatment induced a significant increase in
the fraction of pSTAT3 cells amongwhole bonemarrow cells,
and sgp130 treatment significantly attenuated the PTH-depen-
dent increase in pSTAT3 IL-6/ cells (Fig. 4D). Similar find-
ings were found when the analyses gated on small cells includ-
ing lymphocytes (Fig. 4E), large cells including myeloid lineage
cells (Fig. 4F), and CD11bGr-1 cells, which are myeloid pre-
cursor cells (Fig. 4G). Collectively, sgp130 inhibited PTH-stim-
ulated STAT3 phosphorylation in both lymphocytic and mye-
loid cell populations, suggesting that sIL-6R is critical for
STAT3 activation in response to PTH.
Taken together, not only IL-6 but also IL-6R signaling alone
mediated PTH actions in hematopoietic cell expansions
through STAT3 phosphorylation. Notably, in IL-6 deficient
conditions, actions of sIL-6R signaling on hematopoietic cells
were rapid, suggesting possible compensation.
FIGURE2.Effect of sIL-6Ronexvivohematopoietic cell expansion.A, experimental designof ex vivo cell expansion studywith sIL-6R treatment.Wholebone
marrows from IL-6/ or IL-6/ mice (6 weeks old, female) were seeded at 1.2  105 cells/cm2 with Flt-3L-containing medium and treated once with or
without PTH. Additionally, VEH or sIL-6R (0.5g/ml) was co-treated in each group. Nonadherent cells were enumerated using trypan blue exclusion, and flow
cytometric analysis was performed at days 6 and 8. B and C, numbers of total nonadherent cells from IL-6/ (B) and IL-6/ (C) marrows. D, the percentages
of annexin VPI cells in IL-6/marrows. E, the percentages of annexin VCD11bGr-1 cells from IL-6/marrows. F, representative dot plots of annexin
VCD11bGr-1 cells from PTH-treated IL-6/ marrows at day 6. G, the percentages of annexin VF4/80 cells from IL-6/ marrows. H, representative
histograms of annexin VF4/80 cells from PTH-treated IL-6/ marrows at day 6. All of the numerical data are the means  S.E. of two independent
experiments performed in triplicate. *, p 0.05; **, p 0.01.
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The Role of sIL-6R Signaling on PTH Skeletal Anabolic
Actions—The second aim of this study was to delineate the
relationship between hematopoietic and skeletal actions of
PTH through IL-6 or sIL-6R signaling. To investigate the effect
of IL-6 on PTH actions in bone, intermittent PTH was admin-
istered to male and female IL-6/ and IL-6/ mice at two
different ages, young (3–24 days) for 3 weeks and adult (16–22
weeks) for 6 weeks. Both static and dynamic histomorphomet-
ric analyses andmicroCT analysis demonstrated that PTH sim-
ilarly increased bonemass and bone formation rates in IL-6/
and IL-6/mice (supplemental Fig. S3).
Because sIL-6R alone had biologic effects on hematopoietic
cells in IL-6 deficient conditions, it is possible to deduce that
sIL-6R signaling compensated for the absence of IL-6 in the
skeletal system. To verify this hypothesis, young IL-6/mice
were treated with vehicle, PTH, sgp130 alone, or combined
with PTH for 2 weeks. Histomorphometric analyses showed
that PTH significantly increased fractional bone area, trabecu-
lar number, and trabecular thickness in femurs (Fig. 5A) and
vertebrae (supplemental Fig. S4). sIL-6R inhibition via sgp130
treatment attenuated these skeletal anabolic actions of PTH.
When combined with PTH, sgp130 reduced PTH-dependent
increase in fractional bone area by 26% (p 0.016) and trabec-
ular thickness by 18% (p 0.001) in femurs (Fig. 5A). In verte-
brae, sgp130 also showed a significant attenuation of the PTH-
dependent increase in fractional bone area by 13% (p 0.011)
and trabecular number by 16% (p  0.044) (supplemental Fig.
S4). In addition, TRAP staining of bone sections showed that
PTH increased osteoclast numbers (Fig. 5B, OC. N./BS) and
surface (Fig. 5C,OC. S./BS), and sgp130 treatment significantly
limited the PTH increase in osteoclast numbers. Consistent
with histomorphometric data, comparisons of serum bone
turnover markers also demonstrated that sgp130 reduced
PTH-dependent increases in serum P1NP (Fig. 5D) and
TRAP5b (Fig. 5E).
Because anabolic actions of PTH have recently been associ-
ated with increased TGF-1 protein levels supporting mesen-
chymal stem cell recruitment (29, 30), TGF-1 mRNA and
active protein levels were measured. Mice treated with sgp130
had significantly reduced PTH-dependent increases in TGF-1
mRNA (Fig. 5F) and active protein levels (Fig. 5G).
To discriminate direct versus indirect actions of sIL-6R in the
skeletal system, the direct effect of sIL-6R on osteoblast prolif-
eration and differentiation was investigated using primary cal-
varial cell cultures in vitro. Treatment with sIL-6R (0.1 or 0.5
g/ml) did not alter the number of calvarial cells over time,
suggesting that sIL-6R alone does not directly alter osteoblastic
cell proliferation (supplemental Fig. S5A). Von Kossa staining
FIGURE 3. Effect of sgp130 on ex vivohematopoietic cell expansion. A, experimental design of ex vivo cell expansion studywith sgp130 treatment. Flushed
wholemarrows from IL-6/or IL-6/mice (6weeks old, female)were pretreatedwith VEHor sgp130 (1g/ml) for 1 h and seeded at 1.2 105 cells/cm2with
Flt-3L-containingmedium. At the time of plating, each groupwas treated once with or without PTH. At day 8, nonadherent cells were harvested, enumerated
using trypan blue exclusion, and used for flow cytometric analysis. B and C, numbers of total nonadherent cells from IL-6/ (B) and IL-6/ (C) mice. D, the
percentages of annexin VPI cells in IL-6/marrows. E, the percentages of annexin VCD11bGr-1 cells from IL-6/marrows. F, representative dot plots
of annexin VCD11bGr-1 cells from PTH-treated IL-6/marrows. G–J, plots of the percentages of annexin VF4/80 (G), annexin VCD19 (H), annexin
VCD3 (I), and annexin VB220 (J) cells are shown from IL-6/marrows. All of the numerical data are the means S.E. of two independent experiments
performed in triplicate. *, p 0.05.
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and ostegenicmarker gene studies such as alkaline phosphatase
and osteocalcin showed that there was no difference in miner-
alized nodule formation in calvarial cells with and without
sIL-6R treatment, whereas PTH (10 nM) inhibited mineraliza-
tion in IL-6/ calvarial cells (supplemental Fig. S5, B and C).
Taken together, sIL-6R signaling, not IL-6, support PTH ana-
bolic actions in bone without direct effects on IL-6/ osteo-
blast/stromal cells.
The Role of sIL-6R Signaling on TGF-1 Expressions in Mye-
loid Cells—Because sIL-6R signaling had no direct effects on
osteoblast proliferation or differentiation, we then hypothe-
sized that sIL-6R signaling supported anabolic actions of PTH
in association with expansion of hematopoietic cells and
TGF-1 production. The direct effects of sIL-6R on TGF-1
production in myeloid cells (significantly expanded by sIL-6R
signaling in the ex vivo expansion study Fig. 2, E and F) were
investigated.
IL-6 (20 ng/ml) or sIL-6R (0.5g/ml) at the effective concen-
tration reported for cell stimulation (31) was administered to
whole marrow or myeloid (CD11b) cells ex vivo and TGF-1
gene expression was analyzed. At 2 h, sIL-6R significantly up-
regulated TGF-1 mRNA expression in whole marrow and
myeloid cells in both IL-6/ (Fig. 6A and B) and IL-6/ (Fig.
6, C and D) cells, whereas IL-6 up-regulated TGF-1 only in
IL-6/ whole marrow cells (Fig. 6A). At 12 h, the effects of
sIL-6R disappeared. Collectively, in the bone microenviron-
ment sIL-6R rapidly stimulated myeloid TGF-1 expression,
whereas IL-6 stimulated TGF-1 expression at a slower rate
and to a lesser extent.
DISCUSSION
Recently, growing evidence suggests a regulatory relation-
ship between bone and hematopoietic cells (9). Because PTH
plays a dual function in both systems, it is reasonable to hypoth-
esize that PTH is a bidirectional mediator of the skeletal and
hematopoietic systems. Gp130, a common receptor of the IL-6
cytokine family, is an established regulator of bone modeling
and remodeling (18, 32–34). In addition, IL-6 plays a role in
FIGURE 4. Effect of sIL-6R signaling on STAT3 phosphorylation. A, whole bonemarrow cells from 4-week-old female IL-6/ and IL-6/micewere treated
once ex vivo with VEH, PTH (10 nM), or PTH with 1-h pretreatment of sgp130 (1 g/ml) for 12 h, followed by flow cytometric analysis. The graph shows the
percentages of pSTAT3 cells. B and C, whole bone marrows from 4-week-old female IL-6/ and IL-6/mice were treated once ex vivo with VEH, IL-6 (20
ng/ml), or sIL-6R (0.5 g/ml) for 0.5, 2, 6, and 12 h. The percentages of pSTAT3 cells from IL-6/ (B) and IL-6/ (C) mice are shown. D–G, young (3 weeks)
female IL-6/mice were treated once with VEH or sgp130 (0.3 g) in vivo 1 h prior to treatment with PTH (50 g/kg) or VEH. Two hours later, whole bone
marrows were isolated, and flow cytometric analysis of pSTAT3 cells was performed. D–G, analyses of pSTAT3 cells gated in whole marrows (D), lower side
scattered cells (high end SSC threshold set at 440) representing lymphocytes (E), and higher forward and side scattered cells (F, low end FSC and SSC threshold
set at 420 each) representing granulocytes andmyeloid cells (G, CD11bhighGr-1high). Histograms show gray (VEH), black (PTH), and dotted (PTHsgp130) bars.
All numerical data are themeans S.E. (n 4/group). *, p 0.05; **, p 0.01; ***, p 0.001.NS, not significant; SSC, side scattered cells; FSC, forward scattered
cells.
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hematopoietic cell expansion. Therefore, we hypothesized that
IL-6 and sIL-6R are important mediators in both the skeletal
and hematopoietic systems. To address this, the effect of IL-6
and sIL-6R on anabolic actions of PTH in bone was explored.
Interestingly, sIL-6R signaling supported PTH anabolic actions
in bone, whereas IL-6 did not.
The present study demonstrated that sIL-6R alone (orphan
sIL-6R signaling) plays a role in PTH-mediated hematopoietic cell
expansion. The effect of sIL-6R signaling on hematopoietic cell
expansionwasmore rapid than classic IL-6 signaling, especially in
myeloid cells. Furthermore, sIL-6R signaling, and not IL-6, sup-
ported anabolic actions of PTH in bone. sIL-6R signaling did not
directly affect the osteoblast phenotype but instead up-regulated
myeloid production of TGF-1, a known mesenchymal stem cell
inductive factor, suggesting that sIL-6R signaling mediated PTH
anabolic actions in bone through its supportive actions on hema-
topoiesis, especially via cells in the myeloid linage.
This study provided new and direct evidence that PTH stim-
ulated osteoblastic production of sIL-6R. Intriguingly, the
lower basal level of sIL-6R in IL-6/ osteoblasts was rescued
by PTH stimulation, and this finding was consistently repro-
duced in PTH treatment of young IL-6/mice in vivo. A note-
worthy finding was that the levels of sIL-6R in bone marrow
(200–530 ng/ml) were much higher than in serum (70–200
ng/ml) andPTHup-regulated sIL-6R inmarrow andnot serum,
substantiating an osteoblast role and suggesting the importance
of local actions of sIL-6R in the bone microenvironment that
may not be reflected in an endocrine manner in the serum. In
comparison, the PTH-mediated amplification of endogenous
sIL-6R levels, ex vivo, was restricted in IL-6/ compared with
FIGURE 5. The role of sIL-6R transsignaling on PTH skeletal actions. sgp130 (0.3 g) or vehicle was administrated 1 h prior to PTH (50 g/kg) or VEH
to IL-6/ mice (3 days old) daily for 2 weeks. A, representative hematoxylin and eosin images of femur (original magnification, 100) and plots of
fractional bone area (B.Ar/T.Ar), trabecular number (Tb.N), trabecular thickness (Tb.Th), and cortical width (Ct.Wi). B and C, histomorphometric analyses
of TRAP-stained bone sections including osteoclast number (B, OC.N/BS), and osteoclast surface (C, OC.S/BS). D–F, serum levels of P1NP (D), TRAP 5b (E),
and mRNA (F). G, protein levels of TGF-1 in bone marrow (n 10–13/group). All of the numerical data are the means S.E. *, p 0.05; ***, p 0.001
corresponding to comparisons between VEH () and sgp130 (); #, p  0.05 versus VEH (first bar). NS, not significant. A Student’s t test or a two-way
analysis of variance was used to calculate p values.
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IL-6/ cells. Because more than 90% of sIL-6R is produced
from the cleavage of the membrane-bound sIL-6R through an
ADAM (a disintegrin and metalloproteinase) family protein,
different environmental conditions between in vivo and ex vivo
systems could affect these protein cleavage processes and result
in different PTH responses. Indeed, exogenous sIL-6R treat-
ment effectively increased ex vivo hematopoietic cell expansion
in IL-6/marrows.
Notably, this study found that sIL-6R itself, without IL-6, has
orphan properties in the bone microenvironment. Production
of sIL-6R in response to PTH in IL-6 deficient mice, showed
that sIL-6R mediated downstream STAT3 phosphorylation
independent of IL-6 and in response to PTH. Additionally,
sIL-6R signaling mediated PTH-dependent hematopoietic
cell expansion and anabolic actions in bone as revealed by its
inhibition with sgp130. The sgp130 mediator quenches the
IL-6sIL-6R complex, resulting in interruption of its binding
to gp130, without affecting IL-6 signaling through the classic
IL-6 membrane-bound receptor (35). Future studies where
PTH actions are evaluated when sgp130 is administered to
adult mice and/or in osteoblast-targeted IL-6R deficient
mice could provide further validation of the skeletal actions
found here.
Several emerging lines of data support orphan properties of
sIL-6R over an agonistic function to IL-6. Diamant et al. (36)
first described an orphan effect of sIL-6R on proliferation of B9
cells, which was not neutralized by anti-IL-6 antibody, and
Gabay et al. (37) reported a stimulatory effect of sIL-6R alone on
the production of acute phase protein in hematoma cells or B9
cells. In HepG2 cells, which do not produce endogenous IL-6,
sIL-6R alone up-regulated JunBmRNA expression via a gp130-
dependent manner even in the presence of anti-IL-6 antibody
(38). In addition, microarray analysis of HepG2 cells showed 11
genes regulated by sIL-6R alone and not by the IL-6sIL-6R
complex (39). To our knowledge, this is the first demonstration
of orphan function of sIL-6R in the skeletal and hematopoietic
system and the blocking effect of sgp130 on such sIL-6R orphan
functions.
In this study, ex vivo cell expansions were performed in
IMDM containing 4.5 g/liter glucose. Although high glucose-
induced metabolic stress could affect hematopoiesis (40–42),
cultures in other media containing lower glucose concentra-
tions, such as RPMI (2 g/liter glucose) or -MEM (1 g/liter
glucose) showed similar cell expansions compared with IMDM
(4.5 g/liter glucose) (supplemental Fig. S6), suggesting that the
effects were independent of glucose concentration.
Because osteoblasts express low levels of the membrane
IL-6R (16), the IL-6sIL-6R complex and not IL-6 alone would
have more potential to play a role in osteogenic differentiation
(43, 44) and cell proliferation (43–45). However, in the present
study, sIL-6R signaling had no direct effect on proliferation or
differentiation in IL-6/ osteoblasts, and sgp130 did not
inhibit STAT3 phosphorylation of IL-6/ osteoblasts. In con-
trast, sIL-6R signaling played a role in PTH-mediated hemato-
poietic cell expansion. Exogenous sIL-6R treatment resulted in
hematopoietic cell expansion in a manner similar to PTH, and
blocking endogenous sIL-6R with sgp130 markedly attenuated
the PTH effect on hematopoietic cells in IL-6/ cultures. That
sgp130 inhibited hematopoietic cell expansion in vitro and skel-
etal actions of PTH in vivo, with no direct impact on osteo-
blasts, led us to conclude that PTH-mediated sIL-6R produc-
tion and signaling in hematopoietic cells supports PTH
anabolic actions in bone.
In the present study, the stimulatory effect of PTH on
TGF-1 in bone marrow was attenuated by blocking sIL-6R
signaling with sgp130 in vivo. Furthermore, ex vivo treat-
ment with sIL-6R, not IL-6, rapidly increased TGF-1 gene
expression in myeloid cells, indicating that up-regulation of
TGF-1 in the bone microenvironment is sIL-6R signaling-
preferred. TGF-1 is an osteotropic factor that is activated
FIGURE 6. Ex vivo TGF-1 gene expression study.Whole bonemarrowswere harvested from4-week-old female IL-6/ and IL-6/mice, and CD11b cells
were sorted bymagnetic-activated cell sorting.Wholemarrows or CD11b cells were plated, and VEH, IL-6 (20 ng/ml), or sIL-6R (0.5g/ml) were administered
for 2, 8, and 12 h ex vivo. TGF-1mRNA levels of were analyzed by real time PCR in IL-6/wholemarrow (A), IL-6/myeloid (CD11b) cells (B), IL-6/whole
marrow (C), and IL-6/myeloid (D, CD11b) cells (n 4/group). All of the numerical data are the means S.E. *, p 0.05; **, p 0.01.
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and secreted during osteoclastic bone resorption and
recruits mesenchymal stem cells into remodeling sites (30,
46). Interestingly, treatment with alendronate, which
induced osteoclast cell apoptosis, inhibited the release of
TGF-1 from the bone matrix, resulting in blunted anabolic
actions of PTH (29). The data in the present study corrobo-
rated previous studies (29, 30, 46) and suggested a role for
sIL-6R signaling in TGF-1-related anabolic actions in bone.
A previous report found that STAT3 positively regulated
TGF-1 production through binding to the TGF-1 pro-
moter region, suggesting that TGF-1 is a direct down-
stream target of STAT3 (47), which supports the findings in
the present study. Interestingly, the present study showed
that sIL-6R signaling and IL-6 signaling have differing tem-
poral actions on STAT3 phosphorylation with sIL-6R signal-
ing, resulting in more rapid STAT3 phosphorylation. Collec-
tively, we speculate that sIL-6R signaling up-regulated bone
marrow TGF-1 through its earlier action on STAT3 phos-
phorylation relative to the later action of IL-6.
IL-6 and sIL-6R are up-regulated in various human physio-
logic and pathologic conditions such as aging, cancer, fractures,
and acute or chronic inflammatory diseases. Recently, benefi-
cial effects of PTH on bone formation in fracture healing (48,
49) or osseous wound healing in periodontal disease (3) have
been reported. Our findings provide evidence that potential
therapeutic applications of PTH in such human conditionsmay
be attributed to the integration of IL-6 signaling in the skeletal
and hematopoietic compartments.
In summary (Fig. 7), sIL-6R, secreted in response to PTH
stimulation of osteoblasts, plays an essential role in both PTH-
mediated hematopoietic cell expansion and skeletal anabolism.
In the skeletal system, sIL-6R mediates PTH anabolic actions
through its supportive role in myeloid cell expansion and
TGF-1 production in the bone microenvironment in associa-
tion with gp130/STAT3 signaling. In contrast, IL-6 contributes
to PTH-mediated hematopoietic cell expansion but is dispen-
sable for PTH anabolic actions in bone. This study provided
evidence of the relationship between hematopoietic and skele-
tal systems through PTH and sIL-6R signaling.
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